Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030082 · ClinicalTrials.gov registry record · Phase 1
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00030082: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00030082 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030082, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of hepatic arterial infusion with melphalan in treating patients who have unresectable liver cancer.
Interventions
- DRUG melphalan
- DRUG isolated perfusion
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030082
The ClinicalTrials.gov registry entry for NCT00030082 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00030082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030082 about?
NCT00030082 is a clinical study titled "Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer". RATIONALE: Heating melphalan to several degrees above body temperature and infusing it to the affected area directly around the tumor may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of hepatic arterial infusion with melphalan in treating patients who have unresectable l...
What is the current status of trial NCT00030082?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07.
What interventions are being tested in trial NCT00030082?
The interventions under investigation include: melphalan (DRUG), isolated perfusion (DRUG).
Who is sponsoring clinical trial NCT00030082?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.